Literature DB >> 11762558

The effect of intravenous haloperidol on QT interval dispersion in critically ill patients: comparison with QT interval prolongation for assessment of risk of Torsades de Pointes.

J E Tisdale1, S Rasty, I D Padhi, N D Sharma, H Rosman.   

Abstract

The objective of this study was to determine the effect of intravenous haloperidol on QT interval dispersion in critically ill patients and to compare increases in QT interval dispersion and QTc intervals in patients who developed haloperidol-induced Torsades de Pointes versus those in patients who did not. This was a case-controlled study of 30 critically ill patients who received intravenous haloperidol for delusional agitation. Cases were patients (n = 6) who developed Torsades de Pointes during haloperidol therapy. Controls were patients (n = 24) who did not experience haloperidol-induced Torsades dePointes. QTc intervals were measured and QT interval dispersion was calculated. Haloperidol prolonged QTc interval compared to pretreatment values in Torsades de Pointes patients (606 +/- 61 ms vs. 501 +/- 44 ms, p = 0.007) by a greater magnitude than in patients who did not experience Torsades de Pointes (507 +/- 60 ms vs. 466 +/- 44, p = 0.01). Twelve-lead analysis revealed that QT interval dispersion increased in patients who experienced Torsades de Pointes (from 63 +/- 11 to 95 +/- 22 ms, p = 0.03) but not in those who did not (62 +/- 18 vs. 60 +/- 26 ms, p = 0.66). Analysis of precordial leads only showed no significant haloperidol-associated increases in QTinterval dispersion in eithergroup. The odds of developing haloperidol-induced Torsades de Pointes were highest in patients with QTc interval > 521 ms during haloperidol therapy(odds ratio = 12.1). It was concluded that intravenous haloperidol prolongs QTc intervals in critically ill patients. The degree of prolongation is greater in patients who experience Torsades de Pointes. QT interval dispersion may be increased in patients who develop haloperidol-induced Torsades de Pointes compared with those who do not. However, these effects are dependent on the method of measurement (12 leads vs. precordial leads). In addition, the odds of haloperidol-induced Torsades de Pointes are higherin patients with QTc intervalprolongation compared with increased QT interval dispersion. Therefore, QTc interval determination remains preferable to QT interval dispersion as a means assessment of risk for haloperidol-induced Torsades de Pointes.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11762558     DOI: 10.1177/00912700122012896

Source DB:  PubMed          Journal:  J Clin Pharmacol        ISSN: 0091-2700            Impact factor:   3.126


  14 in total

1.  Changes of QT Dispersion in Hemodialysis Patients after Administrating Zhigancao Decoction ().

Authors:  Yan-Qing Tong; Min Sun; Chun-Jie Hu; Dong-Kai Zhao
Journal:  Chin J Integr Med       Date:  2016-07-19       Impact factor: 1.978

Review 2.  Atypical antipsychotics: from potassium channels to torsade de pointes and sudden death.

Authors:  Karine Titier; Pierre-Olivier Girodet; Hélène Verdoux; Mathieu Molimard; Bernard Bégaud; Wilhelm Haverkamp; Malcolm Lader; Nicholas Moore
Journal:  Drug Saf       Date:  2005       Impact factor: 5.606

3.  The use of low-dose IV haloperidol is not associated with QTc prolongation: post hoc analysis of a randomized, placebo-controlled trial.

Authors:  Matthew S Duprey; Nada Al-Qadheeb; Russel Roberts; Yoanna Skrobik; Greg Schumaker; John W Devlin
Journal:  Intensive Care Med       Date:  2016-09-16       Impact factor: 17.440

Review 4.  Assessing QT interval prolongation and its associated risks with antipsychotics.

Authors:  Jimmi Nielsen; Claus Graff; Jørgen K Kanters; Egon Toft; David Taylor; Jonathan M Meyer
Journal:  CNS Drugs       Date:  2011-06-01       Impact factor: 5.749

5.  A computerized physician order entry set designed to improve safety of intravenous haloperidol utilization: a retrospective study in agitated hospitalized patients.

Authors:  Andrew J Muzyk; Sarah K Rivelli; Wei Jiang; Heather Heinz; Amber Rayfield; Jane P Gagliardi
Journal:  Drug Saf       Date:  2012-09-01       Impact factor: 5.606

6.  Examination of baseline risk factors for QTc interval prolongation in patients prescribed intravenous haloperidol.

Authors:  Andrew J Muzyk; Amber Rayfield; Jane Y Revollo; Heather Heinz; Jane P Gagliardi
Journal:  Drug Saf       Date:  2012-07-01       Impact factor: 5.606

7.  QT interval duration and dispersion in children and adolescents treated with ziprasidone.

Authors:  Christoph U Correll; Johnny D Lops; Vicki Figen; Anil K Malhotra; John M Kane; Peter Manu
Journal:  J Clin Psychiatry       Date:  2011-03-08       Impact factor: 4.384

8.  Haloperidol inhibits the development of atherosclerotic lesions in LDL receptor knockout mice.

Authors:  Ronald J van der Sluis; Joya E Nahon; Anne Q Reuwer; Miranda Van Eck; Menno Hoekstra
Journal:  Br J Pharmacol       Date:  2015-03-16       Impact factor: 8.739

9.  Conventional and atypical antipsychotics in the elderly : a review.

Authors:  Pietro Gareri; Pasquale De Fazio; Mariagrazia Stilo; Guido Ferreri; Giovambattista De Sarro
Journal:  Clin Drug Investig       Date:  2003       Impact factor: 2.859

10.  An in vitro model for assessment of drug-induced torsade de pointes arrhythmia : effects of haloperidol and dofetilide on potential duration, repolarization inhomogeneities, and torsade de pointes arrhythmia.

Authors:  Stefan Dhein; Franziska Perlitz; Friedrich-Wilhelm Mohr
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2008-07-22       Impact factor: 3.000

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.